2fTGH-U3A Cell Line

The 2fTGH-U3A Cell Line is part of a panel of IFNy pathway mutant fibrosarcoma cell lines isolated by chemical mutagenesis of IFNy insensitive reporter cells derived from HT1080 cells. Knockout…

Contributors

Inventor Institute
George Stark Cancer Research UK, London Research Institute: Lincoln's Inn Fields
Cat. #: 151810
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Cancer types: Sarcoma;Sarcoma
Organism: Human
Gender: Male
Model: Mutant
Cancer Types In Detail: Fibrosarcoma;Fibrosarcoma
Product description: The 2fTGH-U3A Cell Line is part of a panel of IFNy pathway mutant fibrosarcoma cell lines isolated by chemical mutagenesis of IFNy insensitive reporter cells derived from HT1080 cells. Knockout genes have been identified and span multiple members of the IFMy pathway. These cell lines are be useful for the in vitro study and comparison of disrupted interferon signalling at multiple points across the IFN pathway. The following cell lines are part of the group of IFN signalling mutants: U4C, U2A, U3A, 2FTGH, U6A, U5A. Each containing a different mutation in the IFN signalling pathway. MCF7/TAMR-7 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-7 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-7 cell.The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells.
Gender: Male
CRISPR: Yes
Conditional: Yes
Production details: Human; HT1080 human sarcoma cell lines transfected with a vector encoding a selectable marker regulated by interferon to create the 2fTGH cell line, enabling selection of mutations in genes encoding components of the interferon signalling pathway. Chemical mutagenesis of the 2fTGH cell line enabled isolation of 10 IFNg signalling mutants.
Cellosaurus ID: CVCL_9469
Parental cell line: HT 1080
disease: Cancer;Cancer
Format: Frozen
Shipping conditions: Dry ice
Growth medium: Parental 2fTGH and mutant cell lines can be grown in DMEM with 10% FCS.
Recommended controls: The wild type 2FTGH human fibrosarcoma as a positive control together with the U5a and U3a IFNB resistant cell lines.
Mycoplasma free: Yes
References:

Haan et al. 2008. J Immunol. 180(2):998-1007. PMID: 18178840.

Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation.

Sun et al. 2004. J Interferon Cytokine Res. 24(6):350-61. PMID: 15212709.

Ectopic expression of toll-like receptor-3 (TLR-3) overcomes the double-stranded RNA (dsRNA) signaling defects of P2.1 cells.

Guo et al. 2000. Virology. 267(2):209-19. PMID: 10662616.

Induction of the human protein P56 by interfero…

Citations And Reviews

Related Tools for Cell lines

Cat. # Tool Name
151425 TR146 Cell Line Key Info View Tool
151629 MEF Raf1 FF/FF KI Cell Line Key Info View Tool
151631 C-Raf KI D486A Cell Line Key Info View Tool
151655 FLYA-13 Cell Line Key Info View Tool
151663 MEF PKCe KO KI Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.